Fibulin-3 fragments are prognostic biomarkers of osteoarthritis incidence in overweight and obese women

J. Runhaar, C. Sanchez, S. Taralla, Y. Henrotin, S.M.A. Bierma-Zeinstra

Erasmus MC University Medical Center Rotterdam, Department of General Practice, The Netherlands

D-BOARD Consortium, an European Committee FP7 Project, UK

Bone and Cartilage Research Unit, Arthropole Liege, University of Liege, CHU Sart-Tilman, Belgium

Artialis SA, Liege, Belgium

Erasmus MC University Medical Center Rotterdam, Department of Orthopedics, The Netherlands

Objective: To determine the association between three fibulin-3 peptides and the incidence of radiographic and clinical knee osteoarthritis (OA).

Design: Women between 50 and 60 years, with a BMI ≥27 kg/m², free of knee OA, were recruited. Using binary logistic regression, the association between baseline concentration of serum fibulin (Fib)3-1, Fib3-2 and Fib3-3 and incidence of clinical and radiographic knee OA after 30 months of follow-up was evaluated.

Results: Baseline and follow-up measurements were available for 241 women with a mean age of 55.9 ± 3.2 years and mean BMI of 31.7 ± 3.6 kg/m². None of the concentrations of the three Fib3 epitopes were associated with the incidence of medial or lateral joint space narrowing (JSN) ≥1.0 mm or the incidence of Kellgren & Lawrence (K&L) grade ≥2 after 30 months. All three Fib3 epitopes were associated with the incidence of the clinical and radiographic ACR-criteria and Fib3-1 and Fib3-3 also with chronic pain at follow-up. When adjusted for the other Fib3 peptide concentrations, only Fib3-1 was significantly associated to the incidence of the American College of Rheumatology (ACR)-criteria (OR 3.2 [1.2 e 8.7]) and chronic pain at follow-up (OR 3.0 [1.2 e 7.7]).

Conclusions: Baseline fibulin-3 concentrations are associated with the incidence of clinical knee OA among middle-aged overweight and obese women. Therewith, they meet the criteria of a prognostic biomarker according to the BIPED biomarker classification for OA. Further validation of the fibulin-3 epitopes seems warranted in order to better distinguish subgroups of individuals at increased risk for knee OA development.

© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Introduction

Osteoarthritis (OA) is a progressive disorder characterized by synovial inflammation, bone remodeling, and degradation of the extracellular matrix of articular cartilage. Currently, the diagnosis of OA is based on clinical and radiographic changes which occur late in disease progression. This method does not allow early detection of structural damage, and it is cumbersome to use in daily practice. Therefore, there is an acute need for reliable biochemical markers that can facilitate the diagnosis of OA and inform prognosis, monitoring, and therapeutic strategies for the disease.

Biochemical markers of bone, synovium, or cartilage turnover have been proposed as tools for the diagnosis and prognosis of OA and for the monitoring of OA treatment. However, at that time, there were no reliable biomarkers for early diagnosis, for the identification of different OA phenotypes, or for use as surrogate clinical end points. Therefore, the discovery of novel OA biomarkers is essential for drug discovery and development, for early diagnosis, and to facilitate individualized treatment to improve clinical outcomes.

Originally discovered by proteomic to be increase in OA urine, the fibulin-3 epitopes (Fib3-1, Fib3-2 and Fib3-3) contain a specific sequence of fibulin-3, an extracellular glycoprotein widely...
distributed in various connective tissues including blood vessels, bone, ligament and cartilage. Fibulin-3 inhibits angiogenesis and chondrocyte differentiation. More precisely, the overexpression of fibulin-3 suppresses chondrocyte differentiation by inhibition of cartilage nodules formation, proteoglycan production and aggrecan gene expression. Further, the overexpression of fibulin-3 selectively maintains the expression of Sox-9 but suppresses the expression of Sox-5 and Sox-6. Fibulin-3 also interacts with the tissue inhibitor of metalloproteinases (TIMPs)-3, which is a matrix bound inhibitor of matrix metalloproteinases (MMPs). Fibulin-3 is known to be cleaved by MMP-1, -2, -3, -7, -9 and -12.

Using immunoassays for Fib3-1 and Fib3-2, two specific amino acid sequences of fibulin-3, we demonstrated that their levels were increased in the serum of patients with severe knee OA compared to age-matched healthy subjects. Using the area under the receiver operating characteristic curve (ROC) analysis, Fib3-1 and Fib3-2 levels discriminated well normal and OA populations.

The aim of this study was to determine the association between three fibulin-3 circulating epitopes and incidence of radiographic and clinical knee OA in middle-aged overweight and obese women, free of radiographic and symptomatic knee OA at baseline, using the PROOF cohort.

Methods

For this study, data of the PROOF study were used. This randomized controlled trial investigated the effects of a diet and exercise program and of oral glucosamine sulphate (double-blind and placebo-controlled) on incidence of knee OA, in a 2 x 2 factorial design. The PROOF study included middle-aged women (50–60 years) with a BMI ≥ 27.0 kg/m² but free of clinical and radiographic knee OA at baseline. Additional inclusion criteria were: mastering Dutch language, free of major comorbidities and in age-matched healthy subjects. Using the area under the receiver operating characteristic curve (ROC) analysis, Fib3-1 and Fib3-2 levels discriminated well normal and OA populations.

The present study selected all subjects with baseline serum and complete follow-up data available. Baseline concentrations of all fibulin-3 fragments were checked for normal-distribution. For each fragment, the univariate association with age, BMI, menopausal status, years since menopause, fat percentage, waist circumference, total cholesterol, glycated hemoglobin (HbA1c), physical activity level, ethnicity, presence of Heberden’s nodes, K&L grade 1 vs 0, varus alignment, history of knee injury, presence of mild symptoms, and the presence of OA in other joints was assessed. Factors with a P-value < 0.02 for their association with the fibulin-3 fragment were selected for a multivariable analysis, wherein those with a P-value < 0.05 were selected. Subsequently, the associations of the each of the three baseline fibulin-3 concentrations separately and all three together with the incidence of knee OA was determined using logistic regression. Stepwise adjustment was applied: no adjustments in model 1; adjustment for baseline age and BMI in model 2 additional adjustment for significant factors from the multivariable analysis and the randomization groups of the original trial (since data originate from a clinical trial, but were used as cohort data) in model 3. Several outcome measures were used for the incidence of knee OA at follow-up: incidence of medial joint space narrowing (JSN) ≥ 1.0 mm, lateral JSN ≥ 1.0 mm and of K&L ≥ 2 for incident radiographic knee OA and incidence of the radiographic + clinical ACR-criteria and of chronic pain as incident clinical knee OA. To enable interpretation of the regression associations, fibulin-3 peptides concentrations were standardized into z-scores. A z-score indicates the number of standard deviations (SDs) that the original value deviates from the population mean. The serum Fib-3-1, Fib-3-2 and Fib-3-3 levels were logarithmically transformed before standardized into z-scores. Results for the regression analyses were also presented as odds ratios per SD increase in log Fib-3 and their corresponding 95% confidence intervals. Statistical analyses were performed with SPSS 20.0 (Chicago, IL). A P-value < 0.05 was defined as statistically significant in all logistic regression analyses.

Results

Immunoassays validation

As previously published, the antisera AS88 and AS94 have a high affinity for Fib3-1 and Fib3-2. Antisera did not recognize complete fibulin-3 or BSA and did not cross-react between Fib3-1 and Fib3-2. Poly33-11 is specific for the Fib3-3 epitope without binding entire fibulin-3, BSA or Fib3-2 (Fig. 1). Linearity was shown by diluting serum samples serially and comparing the observed values with the expected values. For Fib3-3 assay, a recovery rate of 89.6% at 1:4; 102.9% at 1:8; 105.1% at 1:12 and 102.4% at 1:16 was observed (n = 8 performed in triplicate) when sera were diluted in NaCl 0.9% BSA 7%.
Fibulin-3 epitopes in the PROOF study

Out of all women included in the PROOF study with bilateral K&L <2, 241 had complete follow-up data and a serum sample available and were selected for the present study. Baseline characteristics are given in Table 1. Of all baseline factors presented in Table 1, only physical activity level was significantly higher in those selected for the present study compared to those excluded (7097 ± 3798 vs 6246 ± 3335, P = 0.04). Incidence of medial JSN ≥1.0 mm after 30 months was seen in 26 out of 241 women (11%), while lateral JSN was seen in 21 women (9%). Incidence of K&L >2, the ACR-criteria and chronic pain after 30 months occurred in 22 (9%), 20 (8%) and 27 women (11%), respectively.

All three fibulin-3 concentrations showed a non-normal distribution at baseline. Therefore, log-transformed and subsequently Z-transformed concentration levels were used throughout the analyses.

Baseline Fib3-1 and Fib3-2 concentrations had only a borderline significant associations with Heberden’s nodes (P = 0.09) and total cholesterol (P = 0.06) respectively in the multivariable analysis. Fib3-3 was significantly associated to HbA1c (P = 0.02) and borderline significant to ethnicity (P = 0.05) in the multivariable analysis. Hence, model 3 of the Fib3-3 analysis was additionally adjusted for baseline HbA1c level. Log-transformed baseline fibulin-3 concentrations did not differ between overweight and obese individuals (Fib3-1: 2.49 ± 0.01 vs 2.46 ± 0.01 [P = 0.23], Fib3-2: 2.49 ± 0.02 vs 2.48 ± 0.01 [P = 0.62], Fib3-3: 0.97 ± 0.02 vs 0.92 ± 0.02 [P = 0.06] for overweight and obese individuals, respectively).

The associations between the baseline concentrations of the three fibulin-3 epitopes separately and the different incident knee OA measures are presented in Table II and Fig. 2. None of the fibulin-3 epitopes were significantly associated to the incidence of any of the radiographic knee OA measures. Contrary, apart from Fib3-2 and incident chronic pain, all fibulin-3 epitopes were significantly associated to both clinical knee OA measures in the totally adjusted models. Model 3 showed no significant effects for adjustment for randomized intervention groups of the original trial (data not shown). When the analyses were adjusted for each of the baseline fibulin-3 concentrations, only Fib3-1 was significantly associated to incidence of the ACR-criteria (OR 3.21 95% CI 1.19–8.70 in model 3) and chronic pain (OR 3.05 95% CI 1.20–7.71 in model 3). Baseline concentrations of all three epitopes for subjects with (I) and without incidence (NI) ACR-criteria and for chronic pain at follow-up are presented in Fig. 3. The subjects with ACR-criteria incidence had a significant higher Fib3-1 (NI 13.5 ± 3.7 nM vs I 16.1 ± 3.7 nM; P = 0.007), Fib3-2 (NI 18.9 ± 6.8 nM vs I 24.1 ± 15.6 nM; P = 0.0235) and Fib3-3 (9.4 ± 4.5 nM vs 11.5 ± 4.4 nM; P = 0.0290) epitope concentrations at baseline than subjects with non-incidence. Those with a chronic pain incidence had significant higher Fib3-1 (NI 13.5 ± 3.5 nM vs I 16.2 ± 4.8 nM; P = 0.008), but not Fib3-2 or Fib3-3, serum levels than those with no chronic pain incidence.

Next, Fig. 4 presents the course of the epitope’s concentrations over the 30 months follow-up period for subjects with and without incidence ACR-criteria and chronic pain at follow-up. No significant change of Fibulin-3 epitopes over 30 months was observed; Fib3-1: −0.90 ± 4.25 nM vs −2.51 ± 3.61 nM (P = 0.19), Fib3-2: −0.42 ± 6.45 nM vs −1.87 ± 7.754 nM (P = 0.35), Fib3-3: −1.4 ± 3.8 nM vs −2.7 ± 3.8 nM (P = 0.19) for NI and I of ACR-criteria, respectively. For non-incidence and incidence of chronic pain, epitope concentrations were: Fib3-1: 0.91 ± 4.37 nM vs −2.17 ± 3.33 nM (P = 0.27), Fib3-2: −0.42 ± 6.55 nM vs −1.92 ± 5.05 nM (P = 0.20), Fib3-3: −1.5 ± 3.8 nM vs −1.9 ± 3.9 nM (P = 0.62), respectively.

Discussion

We have designed three immunoassays to quantify specific epitopes of fibulin-3 in serum. As our antibodies fail to recognize the native fibulin-3, we anticipate that these epitopes are located in circulatory fragments. Previously, we showed that Fib3-1 and Fib3-2 were not correlated and probably reflected different biologic processes. Fib3-1 was associated with aging and hormonal status, while Fib3-2 was not modified by sex, age, or menopause. Immunostaining, revealed the presence of Fib3-1 and Fib3-2 in chondrocytes and in the extracellular matrix of the superficial layer of fibrillated cartilage, but were absent in the surrounding unfrillated zone. Finally, Fib3-1 and Fib3-2 discriminated well
subjects with knee OA from those who do not have the disease\(^{10}\). Until now, Fib3-3 was not investigated in animal model or human cohort.

In this study, baseline fibrilin-3 epitope concentrations are associated to the incidence of knee OA defined by the radiological and clinical ACR-criteria among middle-aged overweight and obese women. In contrast, fibrilin-3 epitopes are not associated with the knee JSN or the K\&L score individually. Interestingly, Fib3-1 epitope was also related to chronic pain suggesting a relationship between fibrilin-3 epitopes and pain in OA patient. This means that fibrilin-3 epitopes predict more clinical than radiologic features in this population. We have then tried to find in the literature a rationale for this association, but fibrilin-3 remains unexplored in OA. Therefore, our interpretation is speculative and based on observation in other disease conditions. Fibrilin-3 is considered as a key elastogenic protein which control the growth of elastic fibers in ligament. In particular, with other fibrilins, fibrilin-3 binds the monomeric form of elastin (tropoelastin) \textit{in vitro} and is shown to be involved in various aspects of elastic fiber development \textit{in vivo}\(^{21}\). In OA joint, ligament laxity is commonly observed, in early-stage OA, leading to joint instability and then increased strain on joint tissue\(^{22}\). It’s a major risk factor in the development of OA\(^{23}\). Joint instability is a determinant of pain in OA\(^{24,25}\). Therefore, we can emphasize that a degradation of fibrilin-3 is associated with ligament hyperlaxity, joint instability, and subsequently with pain.

Therewith, fibrilin-3 epitopes meet the criteria of a prognostic biomarker according to the BIPED biomarker classification for OA\(^{26}\). Further validation of the fibrilin-3 fragments seems warranted in order to better distinguish subgroups of individuals at increased risk for knee OA development. Of course, a better characterization of the circulating fragments are necessary to better understand fibrilin-3 metabolism in healthy and OA conditions, but also to better interpret the data provided by the immunoassays.

**Table II**

<table>
<thead>
<tr>
<th></th>
<th>Incidence</th>
<th>Model 1(^*)</th>
<th>Model 2(^\updownarrow)</th>
<th>Model 3(^\updownarrow)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medial JSN</strong></td>
<td>11%</td>
<td>1.06 (0.61–1.84)</td>
<td>1.08 (0.61–1.91)</td>
<td>1.06 (0.59–1.91)</td>
</tr>
<tr>
<td>Fib3-1</td>
<td></td>
<td>0.66 (0.38–1.12)</td>
<td>0.65 (0.37–1.12)</td>
<td>0.65 (0.38–1.12)</td>
</tr>
<tr>
<td>Fib3-2</td>
<td></td>
<td>0.89 (0.57–1.37)</td>
<td>0.88 (0.56–1.36)</td>
<td>0.83 (0.53–1.32)</td>
</tr>
<tr>
<td>Fib3-3</td>
<td></td>
<td>0.76 (0.41–1.43)</td>
<td>0.71 (0.38–1.35)</td>
<td>0.65 (0.32–1.31)</td>
</tr>
<tr>
<td><strong>Lateral JSN</strong></td>
<td>9%</td>
<td>0.88 (0.50–1.53)</td>
<td>0.87 (0.49–1.52)</td>
<td>0.89 (0.50–1.58)</td>
</tr>
<tr>
<td>Fib3-1</td>
<td></td>
<td>0.98 (0.61–1.57)</td>
<td>0.98 (0.61–1.58)</td>
<td>0.90 (0.54–1.50)</td>
</tr>
<tr>
<td><strong>K&amp;L (\geq 2)</strong></td>
<td>9%</td>
<td>1.17 (0.68–2.04)</td>
<td>1.27 (0.70–2.30)</td>
<td>1.35 (0.73–2.51)</td>
</tr>
<tr>
<td>Fib3-1</td>
<td></td>
<td>1.17 (0.73–1.87)</td>
<td>1.16 (0.74–1.84)</td>
<td>1.20 (0.75–1.92)</td>
</tr>
<tr>
<td>Fib3-2</td>
<td></td>
<td>1.12 (0.70–1.78)</td>
<td>1.09 (0.68–1.75)</td>
<td>1.21 (0.73–2.00)</td>
</tr>
<tr>
<td><strong>ACR-criteria</strong></td>
<td>8%</td>
<td>2.33 (1.26–4.34)</td>
<td>2.29 (1.21–4.35)</td>
<td>2.70 (1.26–5.75)</td>
</tr>
<tr>
<td>Fib3-1</td>
<td></td>
<td>1.67 (1.07–2.62)</td>
<td>1.68 (1.07–2.65)</td>
<td>1.72 (1.07–2.78)</td>
</tr>
<tr>
<td>Fib3-2</td>
<td></td>
<td>1.69 (1.01–2.82)</td>
<td>1.70 (1.01–2.84)</td>
<td>2.00 (1.10–3.65)</td>
</tr>
<tr>
<td>Fib3-3</td>
<td></td>
<td>2.26 (1.28–3.99)</td>
<td>2.41 (1.31–4.42)</td>
<td>2.62 (1.31–5.23)</td>
</tr>
<tr>
<td><strong>Chronic pain</strong></td>
<td>11%</td>
<td>1.39 (0.92–2.09)</td>
<td>1.39 (0.92–2.08)</td>
<td>1.45 (0.95–2.22)</td>
</tr>
<tr>
<td>Fib3-1</td>
<td></td>
<td>1.43 (0.91–2.23)</td>
<td>1.44 (0.92–2.26)</td>
<td>1.72 (1.01–2.91)</td>
</tr>
</tbody>
</table>

**Bold figures** represent statistically significant odd ratio's.

\(^*\) Unadjusted.

\(^\updownarrow\) Adjusted for age and BMI.

\(^\updownarrow\) Additionally adjusted for significant factors of multivariable analyses and randomized groups of the original study.

**Fig. 2.** Odds ratio's and 95% confidence intervals for all three fibrilin-3 epitopes and the selected outcome measures.
Therefore, the main limitation of this study is the lack of information about the size and the form of the circulating fibulin-3 epitopes. Further, we lack information about the role played by fibulin-3 in OA, making the data interpretation speculative. Fibulin-3 is a ubiquitous protein suggesting that peptides released in the blood stream probably come from different tissues. The tissue specificity of an epitope is not required by OARSI to classify a biomarker in the prognostic biomarkers category. Therefore,
despite this lack of specificity, Fib-3 fragment can be considered as potential prognostic biomarkers. However, we recognize that this lack of tissue specificity could be a major concern to predict disease incidence or progression in a general population developing concomitant diseases. In this study, patients have been selected on the basis of strict criteria, excluding patients with severe vascular diseases and major co-morbidities. Further, Fib-3 peptides did not differ between overweight and obese individuals and are not correlated with the BMI, suggesting that they are not linked to co-morbidity like an increased adiposity in these subjects Therefore, we can considered that Fib fragments changes reflect OA disease condition. One other limitation of this study is that it was performed using samples from overweight and obese women, who are not representative of the general OA population. It is difficult to extrapolate the predictive value of fibulin-3 epitopes to other OA subphenotypes. Further studies investigating the relationship between OA incidence and progression and the level of fibulin-3 epitopes are required to qualify these biomarkers as prognosis biomarkers in general population. Finally, the incidence of OA is low, but common, in this cohort. This means that the number of subjects who developed OA represented a small sample, limiting the power of the statistical analysis. The follow-up of this cohort will allow to increase OA population and perhaps, to confirm these findings.

In this study of overweight and obese middle-aged women at risk for developing knee OA, high serum Fib3-1, Fib3-2 and Fib3-3 levels were significantly associated with increased risk of incidence of symptomatic knee OA 2.5 years later. It is in the early pre-clinical phase that distinguishing subjects who are at risk to develop symptomatic knee OA from those who are not, has the highest priority.

Author contribution

JR contributed to the conception and design of the study including collection and assembly of data, analysis and interpretation of data and critical revision of the article for important intellectual content.

CS contributed to the laboratory work, to the interpretation of data and to the critical revision of the article for important intellectual content.

ST contributed to the laboratory work.

SBZ contributed to conception and design of the study including obtaining of funding, analysis and interpretation of data and critical revision of the article for important intellectual content.

YH contributed to the interpretation of data and to the critical revision of the article for important intellectual content.

All authors approved the final version of the manuscript.

Competing interest statement

Y Henrotin is the founder and president of the university spin-off Artialis sa.

Role of the funding source

The PROOF study had been funded by ZonMw, the Netherlands Organisation for Health Research and Development and the D-Board project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement No. 305815. This work has received partial funding from a program grant of the Dutch Arthritis Foundation for their centre of excellence “Osteoarthritis in primary care”. The funding sources had no role in the study design, collection, analysis or interpretation of data, in the writing of the manuscript or in the decision to submit the manuscript for publication.

Acknowledgments

The authors would like to thank all the participants and staff of the PROOF study, and Dr Myriam Gharbi for her expertise.

References

fluoroscopy, of standing extended, semiflexed (MTP), and schuss views. J Rheumatol 1999;26:2664–74.